Eli Lilly slides slightly to $1,143.53 as ADA2026 event concludes, Eli Lilly and Company posts

Traders Union
All News
Companies
Eli Lilly down 0.49% today

Highlights

LLY is in a strong uptrend, trading well above key moving averages across all timeframes.
Technical indicators are overwhelmingly bullish, but multiple overbought signals suggest the risk of a short-term pullback.
Expected trading range for the coming week is $1,140 to $1,170, with bullish momentum supported by high probability of further price gains.

Bullish structure reinforced as price outpaces moving average supports

LLY is trading at $1,143.53, well above the MA-20 ($1,055.76), MA-50 ($977.78), and MA-200 ($949.74), reinforcing a strong bullish structure across the short, medium, and long-term timeframes. The Ichimoku Kijun on D1 is at $1,062.76, below the current price, marking it as immediate support. Near-term support sits at the Ichimoku Kijun ($1,062.76) and MA-20 ($1,055.76), while key support lies at MA-50 ($977.78). For resistance, the MA-5 ($1,107.45) and MA-10 ($1,099.74) suggest clustered near-term resistance has already been surpassed, making the next notable resistance the 52-week high at $1,182.73.

Persistent upward momentum faces overbought signals amid weekly gains

Momentum is positive, with both MACD and ADX on D1 forecasting a buy scenario, indicating persistent upward strength. However, overbought conditions are apparent: RSI on D1 is elevated at 69.77, CCI signals overbought, and BBP shows significant buyer dominance, while Stoch RSI reads neutral. The Awesome Oscillator aligns with the bullish momentum. LLY has risen $23.48 (2.10%) over the past week, up from a prev_week_close of $1,120.05, and is positioned in the upper part of the weekly range with weekly volatility at 12.27%. The tone reflects continued strength and consolidation near weekly highs.

Uptrend extension favored as overbought risk tempers bullish outlook

The expected trading range for the coming week is $1,140 to $1,170, which is anchored close to the recent high and far above the 52-week low of $624.40, remaining within 3% of the current price. The probability of a price increase is very high (more than 80%), with a much lower likelihood of a sustained decline, based on unanimous bullish signals from W1 RSI, ADX, MACD, and MA-50. The baseline scenario is further consolidation within this corridor. The bullish scenario would see a breakout above $1,170, challenging the record high, while the bearish scenario envisions a pullback toward $1,062 support. This positioning shows LLY is in an extended uptrend, but overbought signals warn short-term pullbacks are possible even as the broader outlook remains bullish.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Eli Lilly maintained a bullish technical outlook, supported by positive clinical trial results and sustained momentum. In light of recent market developments, investors should closely monitor whether the prevailing trend holds above support, as this will be critical in determining the potential for further upside.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.